Lucid Diagnostics Inc
For the period ended Dec 31, 2023. Filed Mar 25, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 25, 2024
LUCD$0.40-4.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| Years Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash flows from operating activities | ||
| Net loss | $(52,666) | $(56,171) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Depreciation and amortization expense | 2,499 | 1,936 |
| Stock-based compensation - Lucid Diagnostics Inc. 2018 Equity Plan | 5,762 | 13,859 |
| Stock-based compensation - PAVmed Inc. 2014 Equity Plan | 1,060 | 1,132 |
| Change in fair value - Senior Secured Convertible Note | 2,980 | — |
| Loss on issue - Senior Secured Convertible Note | 1,111 | — |
| Debt extinguishment loss - Senior Secured Convertible Note | 26 | — |
| APA-RDx: Issue common stock - termination payment | 713 | 653 |
| Issue common stock - vendor service agreement | 23 | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (28) | 183 |
| Prepaid expenses and other current assets | (1,160) | 1,163 |
| Accounts payable | 89 | (445) |
| Accrued expenses and other current liabilities | 2,394 | 333 |
| Due To: PAVmed Inc. - operating expenses, employee related costs, MSA Fee | 4,380 | 7,672 |
| Net cash flows used in operating activities | (32,817) | (29,685) |
| Cash flows from investing activities | ||
| Purchase of equipment | (221) | (908) |
| Asset acquisition | — | (3,200) |
| Net cash flows used in investing activities | (221) | (4,108) |
| Cash flows from financing activities | ||
| Proceeds – issue of preferred stock | 18,625 | — |
| Proceeds – issue of Senior Convertible Note | 10,000 | — |
| Proceeds – issue of common stock – Committed Equity Facility | — | 1,807 |
| Proceeds – issue of common stock – At-The-Market Facility | 284 | — |
| Proceeds – exercise of stock options | — | 695 |
| Proceeds – issue common stock – Employee Stock Purchase Plan | 551 | 109 |
| Net cash flows provided by financing activities | 29,460 | 2,611 |
| Net increase (decrease) in cash | (3,578) | (31,182) |
| Cash, beginning of period | 22,474 | 53,656 |
| Cash, end of period | $18,896 | $22,474 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.